Correction to Lancet Neurol 2022; 21: 417-27

No authors listed

Published Erratum

No authors listed. Lancet Neurol. 2022 Jul.

. 2022 Jul;21(7):e7.

doi: 10.1016/S1474-4422(22)00230-7.

No abstract available

Erratum for

Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial.
Knight EMP, Amin S, Bahi-Buisson N, Benke TA, Cross JH, Demarest ST, Olson HE, Specchio N, Fleming TR, Aimetti AA, Gasior M, Devinsky O; Marigold Trial Group. Knight EMP, et al. Lancet Neurol. 2022 May;21(5):417-427. doi: 10.1016/S1474-4422(22)00077-1. Lancet Neurol. 2022. PMID: 35429480 Clinical Trial.